ArticleBritish journal of cancer2002
High level amplification of N-MYC is not associated with adverse histology or outcome in primary retinoblastoma tumours.
Article in British journal of cancer, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 36 citations in OpenAlex.
- Differentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case-control study.Scientific reports · 2024Article
- Molecular Biological Research on the Pathogenic Mechanism of Retinoblastoma.Current issues in molecular biology · 2024Review
- MRI Features for IdentifyingRadiology · 2023Article
- The OncogeneCancers · 2021Article
- Whole-Genome Sequencing of Retinoblastoma Reveals the Diversity of Rearrangements DisruptingCancers · 2021Article
- Prognostic significance of MYCN gene amplification and protein expression in primary brain tumors: Astrocytoma and meningioma.Cancer biomarkers : section A of Disease markers · 2017Article
- Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma.Cancer medicine · 2017Article
- Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer.Oncotarget · 2015Article
- Didymin induces apoptosis by inhibiting N-Myc and upregulating RKIP in neuroblastoma.Cancer prevention research (Philadelphia, Pa.) · 2012Article
- Insights from mouse models into human retinoblastoma.Cell division · 2008Article
- Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification.The EMBO journal · 2007Article
- KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers.Oncogene · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Twenty-five primary retinoblastoma tumours were analysed by real-time quantitative polymerase chain reaction to determine the genomic copy number of the N-MYC gene (2p24) relative to the copy number for REL, B2M, ALB, AF10 and MLL. Twenty-one of these tumours were shown by Comparative Genomic Hybridization to contain variable copy number increases of chromosomal material mapping to 2p. High level amplification (>30-fold) of N-MYC was found in three tumours, none of which showed adverse histological features and all patients are surviving at between 54 and 108 months post enucleation. Furthermore, the three tumours associated with metastasis and adverse patient outcome showed normal N-MYC copy number. Although high level amplification of N-MYC is an unfavourable prognostic indicator in neuroblastoma, these data show no evidence of a correlation between amplification of N-MYC and adverse outcome in retinoblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.